From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

DS Smith – a pleasing trading update

By Chris Bailey | Monday 10 October 2022

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

A new week and finally some good news from the United States for GSK plc (GSK) as the “FDA approves Boostrix for immunisation during pregnancy for the prevention of whooping cough in newborn infants”. It is not enough alone to start pushing the multinational pharmaceutical and biotechnology FTSE 100 name up, but it is a bit of good news for the company’s struggling CEO. As I have noted before, Dame Emma has a lot still to prove. Meanwhile, elsewhere in the FTSE 100, I am excited to see the over 8% rise in the shares today of DS Smith (SMDS).

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



More house prices comedy

Monday »


Rumours of two placings FWIW